hepatitis-c-virus-hcv-ns-5-a-a-2322-2423-genotype-1a-recomb

Description: Recombinant Hepatitis C virus (genotype 1a) NS5, expressed in E. coli, MW 37.9 kDa. 1.00 mg/mL.

Description: HCV Multiple Antigen (aa 789-1867, 2322-2423), recombinant protein from E. coli.

Description: Mouse Anti-Ovalbumin IgG1 Monoclonal Antibody

Description: Purified recombinant Human Caspase 6 protein

Description: Rabbit polyclonal p21Cip1 antibody

Description: Rabbit polyclonal Arginase 2 antibody raised against the C terminal of ARG2

Description: A synthetic peptide for use as a blocking control in assays to test for specificity of TERF2IP antibody, catalog no. 70R-4063

Description: Mouse monoclonal Keratin K19 antibody

Description: Recombinant Fab monoclonal ST2 antibody

Description: Purified recombinant Human TCEAL3 Protein (His tag)

Description: A competitive inhibition quantitative ELISA assay kit for detection of Arachidonic Acid (AA) in samples from serum, plasma, tissue homogenates or other biological fluids.

Description: A competitive inhibition quantitative ELISA assay kit for detection of Arachidonic Acid (AA) in samples from serum, plasma, tissue homogenates or other biological fluids.

Description: A quantitative ELISA kit for measuring Human in samples from biological fluids.

Description: This ADC product is comprised of an anti-GPC3 monoclonal antibody conjugated via a MC-Vc-PAB linker to SN38

Description: An ADC that is comprised of an anti-human IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to MMAF, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-human IgG Fc specific polyclonal antibody conjugated via a cleavable linker to MMAF, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-human IgG Fc specific polyclonal antibody conjugated via a cleavable linker to MMAE，displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-human IgG Fc specific polyclonal antibody conjugated via a cleavable linker to MD10，displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-human IgG Fc specific polyclonal antibody conjugated via a cleavable linker to DMSA, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-human IgG Fc specific polyclonal antibody conjugated via a cleavable linker to DMDM, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-human IgG Fc specific polyclonal antibody conjugated via a cleavable linker to PNU-159682, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-human IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to DM1, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Fab fragment of an anti-human IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to MMAF,displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Fab fragment of an anti-human IgG Fc specific polyclonal antibody conjugated via a cleavable linker to MMAF, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Fab fragment of an anti-human IgG Fc specific polyclonal antibody conjugated via a cleavable linker to MMAE, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Fab fragment of an anti-human IgG Fc specific polyclonal antibody conjugated via a cleavable linker to DMSA, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Fab fragment of an anti-human IgG Fc specific polyclonal antibody conjugated via a cleavable linker to DMDM, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Fab fragment of an anti-human IgG Fc specific polyclonal antibody conjugated via a cleavable linker to PNU-159682, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Fab fragment of an anti-human IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to DM1, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Fab fragment of an anti-human IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to Alfa-amanitin, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-human IgG Fab specific polyclonal antibody conjugated via a cleavable linker to MMAE, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-human IgG Fab specific polyclonal antibody conjugated via a noncleavable linker to DM1, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening human monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-mouse IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to MMAF, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening mouse monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-mouse IgG Fc specific polyclonal antibody conjugated via a cleavable linker to MMAF, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening mouse monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-mouse IgG Fc specific polyclonal antibody conjugated via a cleavable linker to MMAE, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening mouse monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-mouse IgG Fc specific polyclonal antibody conjugated via a cleavable linker to MD10, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening mouse monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-mouse IgG Fc specific polyclonal antibody conjugated via a cleavable linker to DMSA, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening mouse monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-mouse IgG Fc specific polyclonal antibody conjugated via a cleavable linker to DMDM, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening mouse monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-mouse IgG Fc specific polyclonal antibody conjugated via a cleavable linker to PNU-159682, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening mouse monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-mouse IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to DM1, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening mouse monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Fab fragment of an anti-mouse IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to MMAF, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening mouse monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Fab fragment of an anti-mouse IgG Fc specific polyclonal antibody conjugated via a cleavable linker to MMAF, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening mouse monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Fab fragment of an anti-mouse IgG Fc specific polyclonal antibody conjugated via a cleavable linker to MMAE, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening mouse monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Fab fragment of an anti-mouse IgG Fc specific polyclonal antibody conjugated via a cleavable linker to DMDM, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening mouse monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Fab fragment of an anti-mouse IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to DM1, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening mouse monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-rabbit IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to MMAF, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rabbit monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Fab fragment of an anti-rabbit IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to MMAF, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rabbit monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-rabbit IgG(H+L) specific polyclonal antibody conjugated via a noncleavable linker to MMAF, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rabbit monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-rabbit IgG(H+L) specific polyclonal antibody conjugated via a cleavable linker to MMAF, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rabbit monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-rabbit IgG(H+L) specific polyclonal antibody conjugated via a cleavable linker to MMAE, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rabbit monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Fab fragment of an anti-rabbit IgG(H+L) specific polyclonal antibody conjugated via a noncleavable linker to MMAF, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rabbit monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Fab fragment of an anti-rabbit IgG(H+L) specific polyclonal antibody conjugated via a cleavable linker to MMAF, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rabbit monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-rat IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to MMAF, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rat monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-rat IgG Fc specific polyclonal antibody conjugated via a cleavable linker to MMAF, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rat monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Fab fragment of an anti-rat IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to MMAF, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rat monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Fab fragment of an anti-rat IgG Fc specific polyclonal antibody conjugated via a cleavable linker to MMAF, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rat monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Fab fragment of an anti-rat IgG Fc specific polyclonal antibody conjugated via a cleavable linker to MMAE, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rat monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Fab fragment of an anti-rat IgG Fc specific polyclonal antibody conjugated via a cleavable linker to DMDM, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rat monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of an anti-rat IgG(H+L) specific polyclonal antibody conjugated via a noncleavable linker to MMAF, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rat monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Fab fragment of an anti-rat IgG(H+L) specific polyclonal antibody conjugated via a noncleavable linker to MMAF, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rat monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Fab fragment of an anti-rat IgG(H+L) specific polyclonal antibody conjugated via a cleavable linker to MMAF, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rat monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Protein G conjugated via a VC linker to MMAE, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Protein G conjugated via a linker to MMAF, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Protein G conjugated via a MCC linker to DM1, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Protein G conjugated via a linker to Duocarmycin, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Protein A conjugated via a VC linker to MMAE, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Protein A conjugated via a linker to MMAF, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Protein A conjugated via a MCC linker to DM1, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening monoclonal antibodies as ADC candidates.

Description: An ADC that is comprised of a Protein A conjugated via a linker to Duocarmycin, displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening monoclonal antibodies as ADC candidates.